1. Rev Esp Cardiol (Engl Ed). 2021 Aug;74(8):664-673. doi: 
10.1016/j.rec.2020.06.003. Epub 2020 Jul 11.

Diagnostic yield of sequencing familial hypercholesterolemia genes in 
individuals with primary hypercholesterolemia.

[Article in English, Spanish]

Lamiquiz-Moneo I(1), Civeira F(2), Mateo-Gallego R(3), Laclaustra M(4), 
Moreno-Franco B(5), Tejedor MT(6), Palacios L(7), Martín C(8), Cenarro A(9).

Author information:
(1)Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital 
Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS 
Aragón), Centro de Investigación Biomédica en Red de Enfermedades 
Cardiovasculares (CIBERCV), Zaragoza, Spain.
(2)Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital 
Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS 
Aragón), Centro de Investigación Biomédica en Red de Enfermedades 
Cardiovasculares (CIBERCV), Zaragoza, Spain; Departamento de Medicina, 
Psiquiatría y Dermatología, Universidad de Zaragoza, Zaragoza, Spain. Electronic 
address: civeira@unizar.es.
(3)Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital 
Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS 
Aragón), Centro de Investigación Biomédica en Red de Enfermedades 
Cardiovasculares (CIBERCV), Zaragoza, Spain; Departamento de Fisiatría y 
Enfermería, Universidad de Zaragoza, Zaragoza, Spain.
(4)Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital 
Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS 
Aragón), Centro de Investigación Biomédica en Red de Enfermedades 
Cardiovasculares (CIBERCV), Zaragoza, Spain; Fundación Agencia Aragonesa para la 
Investigación y el Desarrollo (ARAID), Zaragoza, Spain.
(5)Departamento de Microbiología, Medicina Preventiva y Salud Pública, 
Universidad de Zaragoza, Zaragoza, Spain; Unidad de Prevención Cardiovascular, 
Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria 
Aragón (IIS Aragón), Zaragoza, Spain.
(6)Departamento de Anatomía, Embriología y Genética, Universidad de Zaragoza, 
Zaragoza, Spain.
(7)Departamento de I+D, Progenika Biopharma, a Grifols Company, Derio, Vizcaya, 
Spain.
(8)Instituto Biofisika (UPV/EHU, CSIC), Leioa, Vizcaya, Spain.
(9)Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital 
Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS 
Aragón), Centro de Investigación Biomédica en Red de Enfermedades 
Cardiovasculares (CIBERCV), Zaragoza, Spain; Departamento de Bioquímica y 
Biología Molecular, Universidad del País Vasco, UPV/EHU, Bilbao, Spain; 
Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.

INTRODUCTION AND OBJECTIVES: Our objective was to approximate the prevalence of 
mutations in candidate genes for familial hypercholesterolemia (FH) in a 
middle-aged Spanish population and to establish the predictive value of criteria 
for clinical suspicion in the detection of causative mutations.
METHODS: Unrelated individuals aged ≥ 18 years from the Aragon Workers' Health 
Study (AWHS) with high low-density lipoprotein cholesterol (LDL-C) and clinical 
suspicion of FH (participants with LDL-C concentrations above the 95th 
percentile, participants with premature cardiovascular disease and/or 
participants with high LDL-C [130 mg/dL] under statin therapy), assuming that 
any participant with FH exhibits at leats 1 trait, were selected and the LDLR, 
APOB, PCSK9, APOE, STAP1 and LDLRAP1 genes were sequenced by next generation 
sequencing technology.
RESULTS: Of 5400 individuals from the AWHS, 4514 had complete data on lipid 
levels and lipid-lowering drugs, 255 participants (5.65%) met the criteria for 
suspicion of FH, 24 of them (9.41%) were diagnosed with hyperlipoproteinemia(a), 
and 16 (6.27% of those sequenced) were found to carry causative mutations in 
candidate genes: 12 participants carried 11 different pathogenic LDLR alleles 
and 4 participants carried 1 pathogenic mutation in PCSK9. LDL-C concentrations> 
220 mg/dL and LDL-C> 130 mg/dL despite statin therapy showed the strongest 
association with the presence of mutations (P=.011).
CONCLUSIONS: Our results show that the prevalence of FH in Spain is 1:282 and 
suggest that the combination of high untreated LDL-C and high levels of LDL-C 
despite statin therapy are the best predictors of a positive FH genetic test.

Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, 
S.L.U. All rights reserved.

DOI: 10.1016/j.rec.2020.06.003
PMID: 32660911 [Indexed for MEDLINE]